|
|
|
|
Genzyme signs manufacturing deal with Hospira
CAMBRIDGE, Mass.-Biotechnology company Genzyme Corp.is contracting manufacturing for its key products to Hospira Inc. for an undisclosed amount, the company announced last month. The deal involves the manufacturing of the genetic disorder drugs Cerezyme,...
|
|
|
STOCKS NEWS US-Goldman adds St. Jude to 'Conviction Sell' list
stock market report 0820 EST 8Feb2010-Goldman adds St.Jude to 'Conviction Sell' list ------------------------------------------------------------------------------ Goldman Sachs added St. Jude Medical Inc to its conviction sell list, and cut price targets...
|
|
|
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lys
Data sponsored by the Canadian Fabry Disease Initiative (CFDI) to be presented by Dr.Michael West, Dalhousie University CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced that data...
|
|
|
Shire to present important study findings for gaucher
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami,...
|
|
|
Genzyme hires manufacturing chief
NEW YORK - Cambridge-based Genzyme Corp., the drug maker forced to close a plant last year because of contamination, has hired the former head of manufacturing at Eli Lilly & Co., Scott Canute.He joins the company as president of manufacturing and...
|
|
|
Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of...
|
|
|
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lys
CAMBRIDGE, Mass., Feb.3 /PRNewswire-FirstCall/ Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement...
|
|
|
UBS analyst upgrades Genzyme as company resumes shipping enzyme drugs Cerezyme and Fabrazyme
NEW YORK A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to "Buy" from "Neutral," and raised his price target to ...
|
|
|
Ahead of the Bell: Genzyme upgraded to 'Buy'
NEW YORK (AP) - A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to 'Buy' from 'Neutral,' and raised his price...
|
|
|
Ahead of the Bell: Genzyme upgraded to 'Buy'
NEW YORK (AP) -- A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to "Buy" from "Neutral," and raised his price target...
|
|
|
Shire plc to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the
CAMBRIDGE, Mass., Feb.3 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in...
|
|
|
Genzyme Names Global Manufacturing President
CAMBRIDGE, Mass.--Biotechnology company Genzyme Corp.said Wednesday it named Scott Canute president of global manufacturing and corporate operations. Canute previously lead manufacturing at Eli Lilly & Co. At Genzyme, he will oversee production of a...
|
|
|
Genzyme names global manufacturing president
CAMBRIDGE, Mass.--Biotechnology company Genzyme Corp. said Wednesday it named Scott Canute president of global manufacturing and corporate operations. Canute previously lead manufacturing at Eli Lilly & Co. At Genzyme, he will oversee production of...
|
|
|
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lys
CAMBRIDGE, Massachusetts, February 3 /PRNewswire/ -- - Data sponsored by the Canadian Fabry Disease Initiative (CFDI) to be presented by Dr.Michael West, Dalhousie University Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company...
|
|
|
Shire to present important study findings for gaucher disease treatment
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami,...
|
|
|
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium
Companies mentioned in this article: Shire Plc CAMBRIDGE, Mass., Feb.3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for...
|
|
|
From the Editor: Ordinary Measures
Everything I needed to know I learned in Freshman Chemistry 101 To cast your vote, log in or become a member.This quick, one-time registration gives you access to members-only site benefits. 1 vote Text size: - + For Years, pharma has been the villain in...
|
|
|
Genzyme's Outlook Stabilizing
Genzyme Corp.(GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of the...
|
|
|
Genzyme's Outlook Stabilizing - Zibb.com
Company: Genzyme Corp.(GENZ) Genzyme Corp. (GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest...
|
|
|
Genzyme's Outlook Stabilizing
Genzyme Corp.(GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of the...
|
|
|
Genzyme to add 500 jobs
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
|
|
Genzyme chief expects to increase Mass. workforce
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
|
|
Genzyme chief expects to increase Mass. workforce by at least 500
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
|
|
Genzyme: Shire Chomping at the Bit
Previously, I wrote about the significant headwinds Genzyme (GENZ) faces in the next several years ().The JP Morgan Healthcare Conference offered further insight regarding the progress of Genzymes competition in treating Gaucher and Fabry disease. The most...
|
|
|
Genzyme Shifts Gears In Bid For Rebound
5:42 pm EST Last week's news that Genzyme will report a drop in fourth-quarter revenue due to manufacturing problems underscores the biotech's need for better quality control.That need includes avoiding the kinds of problems that led to a viral contamination...
|
